


PRODUCT: SB 939

ALTERNATE NAME: 3-[2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl]-N-hydroxy-2E-propenamide; Pracinostat

CATALOG #: 2285-1, 5

AMOUNT: 1 mg, 5 mg

STRUCTURE:



MOLECULAR FORMULA: C₂₀H₃₀N₄O₂

MOLECULAR WEIGHT: 358.48

CAS NUMBER: 929016-96-6

APPEARANCE: Crystalline solid

SOLUBILITY: DMSO

PURITY: ≥98%

STORAGE: At -20°C. Protect from light and moisture

DESCRIPTION: An orally available pan-histone deacetylase (HDAC) inhibitor binding all HDAC isozymes with similar affinity (K_s = 16-28 nM) with the exception of HDAC6 and 7 (K_s = 247 and 104 nM, respectively). SB 939 demonstrates good bioavailability in vivo and significantly inhibits tumor growth in various xenograft mouse models at doses ranging from 25-100 mg/kg.

REFERENCE: Coffey, D.C., *et al.* (2001). *Cancer Res.* **61**, 3591-3594.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

RELATED PRODUCTS:

CBHA (Cat. No. 2284-5, 10)
 Chidamide (Cat. No. 2261-1, 5)
 CI-994 (Cat. No. 1742-10, 50)
 CUDC-101 (Cat. No. 1966-5, 25)
 Depudecin (Cat. No. 2087-100)
 DiscoveryPak™ HDAC Inhibitor Set (Cat. No. K851-6)
 DiscoveryPak™ HDAC Inhibitor Set II (Cat. No. K876-7)
 M344 (Cat. No. 1701-1)
 MS-275 (Entinostat, MS-275) (Cat. No. 1590-1,5)
 Nexturastat A (Cat. No. 2098-1)
 Nullscript (Cat. No. 2186-1)
 Oxamflatin (Cat. No. 2250-1, 5)
 Panobinostat (LBH589) (Cat. No. 1612-1,5)
 PCI 34051 (Cat. No. 2251-5, 25)
 SAHA (Cat. No. 1604-1)
 SBHA (Cat. No. 2202-50, 250)
 Sodium 4-phenylbutyrate (Cat. No. 1608-100,1000)
 Sodium Butyrate (Cat. No. 1609-1000)
 Splitomycin (Cat. No. 1610-5)
 Trichostatin A (Cat. No. 1606-1)
 Tubacin (Cat. No. 1984-250, 1000)
 Tubastatin A (Cat. No. 1724-1, 5)

USAGE: **FOR RESEARCH CH USE ONLY! Not to be used in humans**